Fennec Pharmaceuticals CEO Jeffrey Hackman Receives 1,159-Share Award

What Happened
Jeffrey S. Hackman, Chief Executive Officer of Fennec Pharmaceuticals, had 1,159 shares acquired on 2026-09-30 at an attributed price of $0.00 (total $0). The filing shows these shares were released from restrictions tied to a prior award rather than purchased or sold.

Key Details

• Transaction date and price: 2026-09-30 @ $0.00 per share (acquisition/award code A).
• Shares involved: 1,159 shares; total reported dollar cost = $0.
• Footnote: These shares were released from restriction from shares awarded 3/28/2025 (per footnote F1).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Filing timeliness: Form 4 was filed on 2026-10-01 (appears timely under the standard two-business-day rule).

Context
This was a release/vesting of previously awarded restricted stock — a common executive compensation event — and does not reflect an open-market purchase or sale. Such releases indicate the shares are no longer restricted, but they do not, by themselves, signal the insider’s intent to buy or sell additional shares.